Table 1.

Patient Demographic and Clinical Characteristics

Characteristic, mean (SD) unless otherwise stated	Stratified by Gd+ lesion during follow-up
	Gd+ Neg.	Gd+ Pos.		Total
	n = 101	n = 65	p Value	N = 166
Female (%)	81 (80.2)	47 (72.3)	0.321	128 (77.1)
Age, y, mean ± SD	43.1 ± 9.8	37.7 ± 9.2	0.001	41.0 ± 9.9
Race, White, %	92 (91.1)	59 (90.8)	0.861	151 (91.0)
EDSS score at baseline
Mean ± SD	3.4 ± 1.8	2.7 ± 1.5	0.017	3.1 ± 1.7
Median [IQR]	3.5 [2.0, 4.0]	2.8 [1.5, 3.5]	0.024	3.0 [2.0, 4.0]
Disease duration, y, mean ± SD	9.8 ± 6.3	8.5 ± 5.4	0.187	9.3 ± 5.96
No. of cumulative Gd+ lesions during follow-up, mean ± SD	0.0a	6.86 ± 9.4	<0.001	2.69 ± 6.8
Weeks until NfL peak after Gd+ lesion
Mean ± SD	—	8.9 ± 14.3	—	—
Median [IQR]	—	8 [0, 12]	—	—
Baseline creatinine clearance, µmol/L, mean ± SD	69.0 ± 11.9	69.8 ± 12.3	—	69.3 ± 12.0

Abbreviations: EDSS = Expanded Disability Status Scale; Gd+ = gadolinium-enhancing; IQR = interquartile range.

^aExclusion criteria of the RESTORE trial included any evidence of Gd-enhancement at screening.